160 related articles for article (PubMed ID: 36462101)
21. Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity.
Zang R; Wang X; Jin R; Lei Y; Huang J; Liu C; Zheng S; Zhou F; Wu Q; Sun N; Gao S; He J
J Transl Med; 2019 Dec; 17(1):430. PubMed ID: 31888670
[TBL] [Abstract][Full Text] [Related]
22. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
23. Combined Effect of Metastasis-Related MicroRNA, miR-34 and miR-124 Family, Methylation on Prognosis of Non-Small-Cell Lung Cancer.
Kim YH; Lee WK; Lee EB; Son JW; Kim DS; Park JY
Clin Lung Cancer; 2017 Jan; 18(1):e13-e20. PubMed ID: 27444357
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C
Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603
[TBL] [Abstract][Full Text] [Related]
25. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging.
Darwiche K; Zarogoulidis P; Baehner K; Welter S; Tetzner R; Wohlschlaeger J; Theegarten D; Nakajima T; Freitag L
Ann Oncol; 2013 Nov; 24(11):2866-70. PubMed ID: 24026539
[TBL] [Abstract][Full Text] [Related]
26. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.
Zhang Y; Zhang Y; Yin Y; Li S
Pathol Res Pract; 2019 Aug; 215(8):152466. PubMed ID: 31146974
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.
Sun L; Zhou H; Yang Y; Chen J; Wang Y; She M; Li C
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32329507
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
30. microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.
Han W; Ren X; Yang Y; Li H; Zhao L; Lin Z
Thorac Cancer; 2020 Jun; 11(6):1679-1688. PubMed ID: 32364673
[TBL] [Abstract][Full Text] [Related]
31. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
[TBL] [Abstract][Full Text] [Related]
32. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer.
Wang RJ; Zheng YH; Wang P; Zhang JZ
Int J Clin Exp Pathol; 2015; 8(1):765-71. PubMed ID: 25755772
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of microRNAs as potential biomarkers in circulating HPV-DNA-positive non-small cell lung cancer patients.
Wu Y; Yin Q; Zhou YL; He L; Zou ZQ; Dai XY; Xia W
Cancer Biol Ther; 2021 Feb; 22(2):136-148. PubMed ID: 33535877
[TBL] [Abstract][Full Text] [Related]
34. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.
Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X
J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758
[TBL] [Abstract][Full Text] [Related]
35. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis.
Ren M; Wang C; Sheng D; Shi Y; Jin M; Xu S
Ann Diagn Pathol; 2017 Apr; 27():57-61. PubMed ID: 28325362
[No Abstract] [Full Text] [Related]
36. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
Li N; Zeng Y; Huang J
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1379-1393. PubMed ID: 32266538
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of Iroquois homeobox 1 methylation in non-small cell lung cancers.
Lee JY; Lee WK; Park JY; Kim DS
Genes Genomics; 2020 May; 42(5):571-579. PubMed ID: 32200543
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
Liu J; Bian T; She B; Liu L; Sun H; Zhang Q; Zhu J; Zhang J; Liu Y
BMC Cancer; 2024 Mar; 24(1):282. PubMed ID: 38429660
[TBL] [Abstract][Full Text] [Related]
39. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection.
Su Y; Fang H; Jiang F
Clin Epigenetics; 2016; 8():109. PubMed ID: 27777637
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR.
He RQ; Cen WL; Cen JM; Cen WN; Li JY; Li MW; Gan TQ; Hu XH; Chen G
Cell Physiol Biochem; 2018; 46(3):925-952. PubMed ID: 29669324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
